Third Pt Reins LTD (TPRE) Holder New Vernon Investment Management Has Trimmed Its Stake as Share Value Declined; Gilead Sciences (GILD) Holder Associated Banc-Corp Has Trimmed Holding as Share Value Declined

June 23, 2018 - By Hazel Jackson

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

New Vernon Investment Management Llc decreased its stake in Third Pt Reins Ltd (TPRE) by 12.02% based on its latest 2018Q1 regulatory filing with the SEC. New Vernon Investment Management Llc sold 25,121 shares as the company’s stock declined 6.36% with the market. The hedge fund held 183,949 shares of the property-casualty insurers company at the end of 2018Q1, valued at $2.57M, down from 209,070 at the end of the previous reported quarter. New Vernon Investment Management Llc who had been investing in Third Pt Reins Ltd for a number of months, seems to be less bullish one the $1.38B market cap company. The stock decreased 0.37% or $0.05 during the last trading session, reaching $13.45. About 2.30M shares traded or 349.06% up from the average. Third Point Reinsurance Ltd. (NYSE:TPRE) has risen 4.33% since June 23, 2017 and is uptrending. It has underperformed by 8.24% the S&P500. Some Historical TPRE News: 04/05/2018 – United Technologies Is in Receipt of a Correspondence From Third Point in Which It Expresses Its Views on the Company’s Portfolio Structure; 09/05/2018 – THIRD POINT REINSURANCE LTD – QTRLY TOTAL REVENUE $140.3 MLN VS $266.5 MLN; 29/03/2018 – REG-Third Point Offshore: Total Voting Rights; 04/05/2018 – THIRD POINT SAYS UTX SPLIT WOULD UNLOCK MORE THAN $20B IN VALUE; 10/05/2018 – EXCLUSIVE-Hedge fund Third Point seeks to launch ‘blank-check’ company; 04/05/2018 – Activist Third Point Pushes for Breakup of United Technologies; 09/05/2018 – Third Point Reinsurance 1Q Rev $140.3M; 14/05/2018 – REG-Third Point Offshore: Suspension of Monthly Share Conversion Scheme; 09/05/2018 – THIRD POINT RE 1Q LOSS/SHR 26C, EST. LOSS/SHR 21C (2 EST.); 04/05/2018 – UNITED TECHNOLOGIES SAYS DISAGREES WITH SEVERAL OF ASSERTIONS CONTAINED IN THIRD POINT LETTER

Associated Banc-Corp decreased its stake in Gilead Sciences Inc (GILD) by 40.64% based on its latest 2018Q1 regulatory filing with the SEC. Associated Banc-Corp sold 21,045 shares as the company’s stock declined 17.62% with the market. The institutional investor held 30,735 shares of the health care company at the end of 2018Q1, valued at $2.32 million, down from 51,780 at the end of the previous reported quarter. Associated Banc-Corp who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $92.41B market cap company. The stock decreased 0.63% or $0.45 during the last trading session, reaching $71.07. About 4.11M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 23, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 25/04/2018 – GALAPAGOS NV GLPG.AS – AIMS TO REPORT TOPLINE RESULTS WITH TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB STUDY; 05/03/2018 – GILEAD SCIENCES – THROUGH 48 WEEKS, BIKTARVY FOUND NON-INFERIOR TO ABACAVIR-CONTAINING REGIMEN IN VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV; 05/03/2018 – GLAXOSMITHKLINE PLC – VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS; 14/05/2018 – Gilead’s Epclusa Falls After 3-Wk Rise, Mavyret Advances: Hep-C; 17/05/2018 – GILEAD, CELGENE, NOVARTIS NAMED MULTIPLE TIMES IN FDA LIST; 01/05/2018 – Gilead Sciences Declares Dividend of 57c; 31/05/2018 – Gilead Sciences Coverage Assumed by PiperJaffray at Overweight; 30/04/2018 – Gilead’s Descovy Falls For 2nd Wk, Odefsey Declines: HIV; 18/05/2018 – EU warns of possible birth defect link to GSK’s HIV drug; 30/04/2018 – GILEAD & VERILY REPORT SCIENTIFIC PACT

Since March 20, 2018, it had 0 buys, and 1 insider sale for $1.47 million activity.

Another recent and important Third Point Reinsurance Ltd. (NYSE:TPRE) news was published by Globenewswire.com which published an article titled: “Research Report Identifies Ballard Power, Melco Resorts & Entertainment, CyberArk Software, Third Point Reinsurance …” on June 04, 2018.

Investors sentiment decreased to 1.34 in 2018 Q1. Its down 1.92, from 3.26 in 2017Q4. It fall, as 16 investors sold TPRE shares while 43 reduced holdings. 19 funds opened positions while 60 raised stakes. 70.59 million shares or 53.40% less from 151.48 million shares in 2017Q4 were reported. Citadel Advsr Ltd Co invested in 0% or 172,696 shares. Alliancebernstein LP owns 342,770 shares for 0% of their portfolio. Virtu Fin Ltd Liability Com accumulated 10,093 shares. Ellington Management Grp Ltd Liability holds 21,400 shares or 0.02% of its portfolio. Credit Suisse Ag owns 112,970 shares for 0% of their portfolio. Legal And General Gp Public Ltd holds 176,036 shares. Horizon Kinetics Lc invested in 27,754 shares or 0.01% of the stock. Pnc Financial Grp reported 0% in Third Point Reinsurance Ltd. (NYSE:TPRE). Optimum Investment holds 0% or 700 shares in its portfolio. Price T Rowe Assocs Md invested in 0.01% or 2.61 million shares. Allen Inv Ltd Company stated it has 125,000 shares or 0.07% of all its holdings. Arbiter Capital Mngmt Ltd owns 106,850 shares or 0.18% of their US portfolio. Blackrock Inc, a New York-based fund reported 10.83 million shares. Northern Corporation accumulated 0% or 1.11 million shares. Mason Street Advsr Lc accumulated 0.01% or 23,208 shares.

Among 6 analysts covering Third Point Reinsurance (NYSE:TPRE), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Third Point Reinsurance had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Keefe Bruyette & Woods maintained it with “Buy” rating and $16.5 target in Friday, September 8 report. As per Friday, November 10, the company rating was maintained by Morgan Stanley. The stock has “Market Perform” rating by Wood on Thursday, October 1. As per Tuesday, April 3, the company rating was maintained by Bank of America. The stock of Third Point Reinsurance Ltd. (NYSE:TPRE) has “Outperform” rating given on Friday, May 11 by Wood. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Monday, December 4 report. The rating was maintained by Keefe Bruyette & Woods with “Buy” on Tuesday, October 10. Compass Point maintained it with “Buy” rating and $16.0 target in Wednesday, September 2 report. The stock of Third Point Reinsurance Ltd. (NYSE:TPRE) has “Buy” rating given on Thursday, August 3 by Keefe Bruyette & Woods. On Monday, May 8 the stock rating was upgraded by Keefe Bruyette & Woods to “Outperform”.

Analysts await Third Point Reinsurance Ltd. (NYSE:TPRE) to report earnings on August, 1. They expect $0.42 earnings per share, down 40.85% or $0.29 from last year’s $0.71 per share. TPRE’s profit will be $42.94M for 8.01 P/E if the $0.42 EPS becomes a reality. After $-0.26 actual earnings per share reported by Third Point Reinsurance Ltd. for the previous quarter, Wall Street now forecasts -261.54% EPS growth.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.42 EPS, down 43.43% or $1.09 from last year’s $2.51 per share. GILD’s profit will be $1.85 billion for 12.51 P/E if the $1.42 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 3.65% EPS growth.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Friday, February 12. Standpoint Research initiated the stock with “Buy” rating in Wednesday, February 3 report. Cowen & Co maintained the shares of GILD in report on Monday, September 21 with “Buy” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Neutral” rating by Citigroup on Wednesday, February 8. The rating was maintained by Cowen & Co on Tuesday, July 25 with “Buy”. The company was maintained on Wednesday, May 2 by Morgan Stanley. Citigroup maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, April 29 with “Buy” rating. On Monday, February 5 the stock rating was maintained by Mizuho with “Buy”. As per Monday, August 28, the company rating was maintained by Maxim Group. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Berenberg on Monday, September 12.

Investors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It improved, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Cypress Asset Management Tx, a Texas-based fund reported 17,630 shares. Bartlett & Limited Co reported 0.94% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Gateway Inv Advisers Lc owns 0.49% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 735,325 shares. Denali Limited Liability Company reported 141,103 shares. Macguire Cheswick & Tuttle Inv Counsel Limited Liability Co holds 0.33% or 23,626 shares. Continental Advsrs Limited Liability invested 1% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). British Columbia Inv Mgmt Corp reported 724,929 shares or 0.42% of all its holdings. Wendell David Assoc owns 31,818 shares. Selway Asset accumulated 17,650 shares. 7,807 were accumulated by Jnba. 137,476 were accumulated by Conning. Tarbox Family Office Inc reported 6,579 shares. Bristol John W & reported 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cleararc owns 29,858 shares. Banque Pictet And Cie stated it has 134,154 shares.

Since January 2, 2018, it had 0 insider purchases, and 23 selling transactions for $48.21 million activity. 50,000 shares valued at $3.68 million were sold by MARTIN JOHN C on Tuesday, January 2. Alton Gregg H also sold $1.18M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. $4.68 million worth of stock was sold by WILSON GAYLE E on Friday, February 9. Another trade for 5,000 shares valued at $401,566 was sold by Washington Robin L. 100,000 shares were sold by Meyers James R, worth $8.02M on Tuesday, January 16.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>